Shots:

• QIAGEN has received the FDA’s EUA for its newly developed QIAstat-Dx Respiratory SARS-CoV-2 Panel test for diagnosing patients infected with the novel COVID-19
• The syndromic test will be deployed in pandemic and can differentiate the SARS-CoV-2 coronavirus from 21 other serious respiratory infections in patients showing similar symptoms. The kit requires < 1min. for preparing the sample and delivers results in ~1hr
• The QIAstat-Dx test is a multiplexed nucleic acid test that assesses samples such as nasopharyngeal swabs obtained from individuals suspected of the respiratory tract and is intended to be used in laboratories certified under CLIA to perform moderate and high complexity tests

Click here ­to­ read full press release/ article | Ref: QIAGEN | Image: QIAGEN